[updated February 24, 1999]

 
 
 

Table 3. Outcomes by treatment group and year since randomization*


 
Estrogen-Progestin
Placebo
Outcome and Period
 No. 
Rate†
 No. 
Rate†
RH (95% CI)
P value‡
Primary CHD event§
    Year 1

  57

42.5

38

28.0
1.52 (1.01-2.29)

0.03
    Year 2
  47
36.9
49
37.8
 0.98 (0.66-1.46)  
   Year 3
  35
28.7
42
33.9
 0.85 (0.54-1.33)  
   Year 4 and 5
  40
28.0
53
37.4
 0.75 (0.50-1.13)  
Nonfatal myocardial infraction
   Year 1

  42

31.3

29

21.3
1.47 (0.91-2.36)

0.05
   Year 2
  33
25.9
38
29.3
 0.89 (0.56-1.41)  
   Year 3
  20
16.4
29
23.4
 0.70 (0.40-1.24)  
   Year 4 and 5
  27
18.9
38
26.8
 0.70 (0.43-1.15)  
CHD death
   Year 1

  17

12.5

11

8.0
1.56 (0.73-3.32)

0.22
   Year 2
  19
14.4
13
9.7
 1.48 (0.73-2.99)  
   Year 3
  18
14.0
17
13.0
 1.07 (0.55-2.08)  
   Year 4 and 5
  16
10.4
18
11.7
 0.89 (0.46-1.75)  
Unstable angina or coronary
revascularization
   Year 1


101


77.0


95


71.8

1.07 (0.81-1.42)


0.96
   Year 2
  53
44.0
86
71.4
 0.62 (0.44-0.87)  
   Year 3
  70
62.6
57
51.5
 1.22 (0.86-1.73)  
   Year 4 and 5
  62
48.5
73
59.5
 0.81 (0.58-1.14)  
Venous thromboembolic event
   Year 1

  13

9.6

  4

2.9
3.29 (1.07-10.1)

0.13
   Year 2
    8
6.1
  2
1.5
 4.09 (0.87-19.3)  
   Year 3
    7
5.5
  3
2.3
 2.39 (0.62-9.26)  
   Year 4 and 5
    6
4.0
  4
2.6
 1.52 (0.43-5.40)  


* RH indicates relative hazard; CI, confidence interval; and CHD, coronary heart disease.
† Event rates per 1000 women-years in the estrogen plus progestin or placebo group.
‡ P values for tests of continuous trend over time in log-relative hazard.
§ Primary CHD events include nonfatal MI and CHD death.